New Market Study Published: Amarantus Bioscience Holdings, Inc. (AMBS) - Product Pipeline Analysis, 2013 Update
Amarantus Bioscience Holdings, Inc. (Amarantus BioScience) is a biotechnology company. The company discovers and develops treatments and diagnostics for diseases associated with neurodegeneration and apoptosis. Its therapeutics includes parkinson's disease, ischemic heart disease and traumatic brain injury. Amarantus BioScience has acquired rights to two diagnostic platforms for the diagnosis of neurodegenerative diseases and oncology such as nuropro diagnostic blood test platform and lympro Alzheimer's disease diagnostic blood test.
View full press release